Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 18, 2020 18:19 ET | Source: Immutep Limited

Immutep Announces Expansion of TACTI-002 Collaboration Trial

Additional 74 patients with 1st line non-small cell lung cancer (NSCLC) to be enrolled, more than tripling patient numbers in this indicationFollows encouraging interim data from 1st line NSCLC...
November 18, 2020 17:59 ET | Source: Immutep Limited

Immutep Completes a A$29.6 Million Placement to Accelerate and Broaden its Clinical Development

Sydney, Australia, Nov. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) : Australian biotechnology company Immutep Limited (“Immutep“ or the “Company“), which is listed on...
November 09, 2020 16:10 ET | Source: Immutep Limited

Immutep’s Phase II TACTI-002 Study Reports Encouraging Data at SITC

Sydney, Australia, Nov. 10, 2020 (GLOBE NEWSWIRE) -- ASX/Media Release...
November 09, 2020 08:00 ET | Source: Immutep Limited

Immutep Announces Australian Patent Grant For IMP701 Antibody

Sydney, Australia, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or the “Company”) announces the grant of patent no. 2015229103 entitled “Antibody molecules...
November 02, 2020 17:24 ET | Source: Immutep Limited

Immutep’s TACTI-002 Data to Be Presented at Society for Immunotherapy of Cancer 2020 Annual Meeting

SYDNEY, Australia, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
October 29, 2020 08:45 ET | Source: Immutep Limited

Immutep to Collaborate with LabCorp to Develop Oncology Services and Products

SYDNEY, Australia, Oct. 29, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP), a biotechnology company developing novel immunotherapy treatments for cancer and autoimmune disease, is...
October 23, 2020 08:00 ET | Source: Immutep Limited

Immutep Announces the Start of an Investigator-Initiated Phase II Study in COVID-19 Patients

Investigator-initiated, placebo controlled and randomized Phase II study evaluating eftilagimod alpha (“efti”) in up to 110 COVID-19 patientsImmutep supplies efti to University Hospital Pilsen, Czech...
October 21, 2020 18:45 ET | Source: Immutep Limited

Immutep Activities Report for the First Quarter of Fiscal Year 2021

Encouraging clinical results from TACTI-002 and INSIGHT-004 trials of eftilagimod alphacompleted recruitment for Stage 1 of Part B in TACTI-002 StudyGranted United States patent relating to...
October 21, 2020 08:00 ET | Source: Immutep Limited

Immutep Granted European Patent for IMP761

SYDNEY, Australia, Oct. 21, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...
October 19, 2020 08:00 ET | Source: Immutep Limited

Immutep to Present AIPAC Overall Survival Data at the San Antonio Breast Cancer Symposium 2020

SYDNEY, Australia, Oct. 19, 2020 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company developing novel immunotherapy treatments for...